EFSA gut/immune health meeting

Health claims: Is the idea of disease risk factors, itself diseased?

By Shane Starling

- Last updated on GMT

Bischoff: Who will answer the "open questions"?
Bischoff: Who will answer the "open questions"?
Differentiating between disease risk factors and disease reduction in the way that the 2006 nutrition and health claim regulation does is too arbitrary and needs revision, according to a German nutrition professor. But if such a change is needed, who should lead the charge?

At the recent European Food Safety Authority (EFSA) gut/immune function meeting in Amsterdam, Stephan Bischoff, PhD, professor and chair at the Department of Nutritional Medicine at the University of Hohenheim, said EFSA’s very own health claims panel could be a good place to start.

Professor Bischoff called on the Panel on Dietietic Products, Nutrition and Allergies (NDA) to address this and other “open questions”.

“The question to me is whether the panel is ready to work on these open questions or whether they have the expectation that the scientists and the companies have to solve all these questions,” ​he said. “Somebody has to solve it, this is very clear now.”

An example is antibiotic associated diarrhoea, which Dr Bischoff believes should be treated as a risk factor to disease, not a disease itself.

“The scientists [on the NDA panel] should stand up and say, this is not possible what you are asking us. They should realise there are limitations to fulfil the criteria of the regulation.”

Related news

Show more

Related products

show more

BB536 for optimal Gut health and beyond

BB536 for optimal Gut health and beyond

Content provided by Morinaga Milk Industry Co., Ltd. | 03-Oct-2024 | White Paper

Among the various probiotics strains available, Bifidobacterium longum BB536 stands out due to its well-documented safety, efficacy, and regulatory approvals....

Unlock sensory innovation with AromatiQ™ technology

Unlock sensory innovation with AromatiQ™ technology

Content provided by Lonza | 20-Sep-2024 | Product Brochure

With 70% of consumers willing to pay a premium for a more enjoyable and memorable supplement experience, Lonza’s new AromatiQ™ technology enables brands...

Related suppliers

Follow us

Products

View more

Webinars